Please assess the completion status of the following clinical trial:

Trial Title: A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 18.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female volunteers, age ≥ 18 years old at screening~2. If female, must be post-menopausal or status post hysterectomy~3. Able to comprehend and to give informed consent~4. Able to cooperate with the Investigator, to comply with the requirements of the study, and to complete the full sequence of protocol-related procedures~Exclusion Criteria:~1. Clinically significant medical history (including von Willebrand Disease, thrombocytopathy, or any type of bleeding diathesis) or ongoing chronic illness that would jeopardize the safety of the subject or compromise the quality of the data derived from his/her participation in this study~2. Clinically relevant abnormal findings on physical examination or clinically relevant laboratory abnormalities~3. History of infusion hypersensitivity reactions, significant drug allergy, or anaphylactic reactions~4. Substance abuse, mental illness, or any reason that makes it unlikely in the judgment of the Investigator for the subject to be able to comply fully with study procedures~5. Use of medication during 2 weeks before the start of the study, which in the judgment of the Investigator may adversely affect the subject's welfare or the integrity of the study's results~6. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 30 days or 5 elimination half-lives (whichever is longer) prior to treatment start

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- BT200 0.18mg (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous dose of BT200 0.18mg
- BT200 0.6mg (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous dose of BT200 0.6mg
- BT200 1.8mg (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous dose of BT200 1.8mg
- BT200 6.0mg (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous dose of BT200 6.0mg
- BT200 12.0mg (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous dose of BT200 12.0mg
- BT200 24.0mg (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous dose of BT200 24.0mg
- BT200 24.0mg rep (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous (SC) dose of BT200 24.0mg by gradual SC infusion
- Placebo SAD (Type: PLACEBO_COMPARATOR): Subjects will receive a single subcutaneous dose of placebo
- BT200 loading dose 12.0mg, maintenance doses of 12.0 mg (Type: EXPERIMENTAL): Subjects will receive an initial subcutaneous loading doses of BT200 12.0mg followed by 4 weekly (every 7 days) maintenance doses of BT200 12.0mg
- BT200 loading doses 24.0mg, maintenance doses of 24.0 mg (Type: EXPERIMENTAL): Subjects will receive an initial subcutaneous loading dose of BT200 24mg followed by 4 weekly (every 7 days) maintenance doses of BT200 24mg
- Placebo MAD (Type: PLACEBO_COMPARATOR): Subjects will receive an initial subcutaneous loading dose of Placebo followed by 4 weekly (every 7 days) maintenance doses of placebo
- BT200 48.0mg + desmopressin challenge (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous dose of BT200 48.0mg followed by IV infusion (over 30 min) of 0.3µg/kg desmopressin administered 24 hours after single dose of BT200
- Placebo + desmopressin challenge dose (Type: PLACEBO_COMPARATOR): Subjects will receive a single subcutaneous dose of placebo followed by IV infusion (over 30 min of 0.3µg/kg desmopressin administered 24 hours after single dose of placebo
- Placebo infusion (Type: PLACEBO_COMPARATOR): Subjects will receive a single IV dose of placebo administered over 24 hours
- BT200 36.0mg (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous (SC) dose of BT200 36.0mg by gradual SC infusion
- BT200 48.0 mg (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous dose (SC) of BT200 48.0mg by gradual SC infusion
- BT200 18.0 mg (Type: EXPERIMENTAL): Subjects will receive a single subcutaneous (SC) dose of BT200 18.0mg by gradual SC infusion
- BT200 24mg IV infusion (Type: EXPERIMENTAL): Subjects will receive a single IV dose of BT200 24mg administered over 24 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete